is glp 1 a specialty drug Addressing GLP-1 Access and Adherence Challenges with Pharmacy Solutions Interested in a weight loss

Since you feel full quickly on GLP-1s, eating large meals can quickly become uncomfortable

What raises concerns are some of the recent reports of serious ADRs associated with GLP-1RAs: (i) Pfizers disclosure of elevated aminotransferases in users of lotiglipron (a novel oral GLP-1RA) is indicative of hepatocellular injury [11]

[DOI] [PubMed] [Google Scholar] 27.Holman R.R., Bethel M.A., Mentz R.J., Thompson V.P., Lokhnygina Y., Buse J.B., Chan J.C., Choi J., Gustavson S.M., Iqbal N., et al

Moreover, in vitro metformin treatments enhanced GLP-1R and PPAR- expression in INS-1 rat -cells [23]

The Thr13 forms a hydrogen bond with Tyr197, while Asp15 forms an ionic bond with R299

Based on the research and clinical trials, here are the disease states and associated risk reductions with GLP-1 medications: Cardiovascular Disease: Major adverse cardiovascular events (MACE): 20-26% reduction Heart attack: ~20% reduction Stroke: ~20% reduction Cardiovascular death: ~15-20% reduction Heart Failure: Heart failure with preserved ejection fraction (HFpEF): Improved symptoms, exercise tolerance, and body composition Heart failure hospitalizations: Reduced (specific percentages vary by study) Kidney Disease: Progression to end-stage renal disease: 20-30% reduction Decline in eGFR: Slowed progression Type 2 Diabetes: Progression from prediabetes to diabetes: Reduced risk (specific percentage varies) Liver Disease: NAFLD/NASH improvement: Reduced liver fat and inflammation Liver enzyme normalization: Significant improvement in ALT/AST Obesity-Related Complications: Body weight reduction: 10-15% (semaglutide), 15-22% (tirzepatide) Visceral fat reduction: Substantial decrease Metabolic Syndrome Components: Blood pressure: 5-10 mmHg reduction in systolic BP Triglycerides: 20-30% reduction Insulin resistance: Significant improvement Cancer: (emerging data) Overall cancer risk: Potential reduction (10-20% suggested in some observational studies) Specific cancers linked to obesity/metabolic dysfunction: Reduced risk observed Neurodegeneration: (preliminary data) Alzheimers disease progression: Some trials are ongoing, but recent data have been unpromising